JP2020526584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526584A5 JP2020526584A5 JP2020522279A JP2020522279A JP2020526584A5 JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5 JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr2
- cdr3
- antibody
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023088505A JP2023116554A (ja) | 2017-06-28 | 2023-05-30 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
| JP2025013074A JP2025069272A (ja) | 2017-06-28 | 2025-01-29 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762525993P | 2017-06-28 | 2017-06-28 | |
| US62/525,993 | 2017-06-28 | ||
| PCT/US2018/039445 WO2019005756A1 (en) | 2017-06-28 | 2018-06-26 | CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088505A Division JP2023116554A (ja) | 2017-06-28 | 2023-05-30 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020526584A JP2020526584A (ja) | 2020-08-31 |
| JP2020526584A5 true JP2020526584A5 (enExample) | 2021-08-05 |
Family
ID=64742639
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522279A Pending JP2020526584A (ja) | 2017-06-28 | 2018-06-26 | 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用 |
| JP2023088505A Pending JP2023116554A (ja) | 2017-06-28 | 2023-05-30 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
| JP2025013074A Withdrawn JP2025069272A (ja) | 2017-06-28 | 2025-01-29 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088505A Pending JP2023116554A (ja) | 2017-06-28 | 2023-05-30 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
| JP2025013074A Withdrawn JP2025069272A (ja) | 2017-06-28 | 2025-01-29 | 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11613588B2 (enExample) |
| EP (1) | EP3645041A4 (enExample) |
| JP (3) | JP2020526584A (enExample) |
| CA (1) | CA3068672A1 (enExample) |
| WO (1) | WO2019005756A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068672A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
| CN112839962A (zh) | 2018-10-09 | 2021-05-25 | 百时美施贵宝公司 | 用于治疗癌症的抗mertk抗体 |
| EP3930847B1 (en) * | 2019-02-26 | 2024-02-14 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
| CN114364703A (zh) * | 2019-04-19 | 2022-04-15 | 豪夫迈·罗氏有限公司 | 抗mertk抗体及它们的使用方法 |
| EP4072680A1 (en) | 2019-12-13 | 2022-10-19 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| MX2023008339A (es) * | 2021-01-15 | 2023-10-04 | Scherer Technologies Llc R P | Conjugados anticuerpo-fármaco de camptotecina y métodos de uso de estos. |
| US20240279347A1 (en) * | 2021-05-14 | 2024-08-22 | Inspirna, Inc. | Mertk peptides and uses thereof |
| EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
| WO2025070337A1 (ja) * | 2023-09-25 | 2025-04-03 | アステラス製薬株式会社 | 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| EP0799244A1 (en) | 1995-10-16 | 1997-10-08 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP1233987B1 (en) | 1999-11-29 | 2009-08-19 | Bac Ip B.V. | Immobilized single domain antigen-binding molecules |
| PT2357006E (pt) | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| EP1825005B1 (en) | 2004-11-24 | 2015-07-15 | The Regents of the University of Colorado, a body corporate | Mer diagnostic and therapeutic agents |
| EP2902495B1 (en) | 2007-11-09 | 2019-12-25 | The Salk Institute for Biological Studies | Use of tam receptor activators as immunosuppressors |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009246516B2 (en) | 2008-05-13 | 2015-03-05 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| CA2808668A1 (en) | 2010-08-19 | 2012-02-23 | Howard Florey Institute | Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease |
| US20150315552A1 (en) * | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| TW202330606A (zh) * | 2014-03-21 | 2023-08-01 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| CA2972048C (en) * | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| CA3068672A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
| EP3930847B1 (en) * | 2019-02-26 | 2024-02-14 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
-
2018
- 2018-06-26 CA CA3068672A patent/CA3068672A1/en active Pending
- 2018-06-26 JP JP2020522279A patent/JP2020526584A/ja active Pending
- 2018-06-26 EP EP18823981.8A patent/EP3645041A4/en not_active Withdrawn
- 2018-06-26 WO PCT/US2018/039445 patent/WO2019005756A1/en not_active Ceased
- 2018-06-26 US US16/626,456 patent/US11613588B2/en active Active
-
2022
- 2022-12-06 US US18/062,355 patent/US12162942B2/en active Active
-
2023
- 2023-05-30 JP JP2023088505A patent/JP2023116554A/ja active Pending
-
2025
- 2025-01-29 JP JP2025013074A patent/JP2025069272A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526584A5 (enExample) | ||
| FI3930847T3 (fi) | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä | |
| JP2022101693A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| JP2023022328A5 (enExample) | ||
| RU2016117810A (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| HRP20200283T1 (hr) | Protutijela koja se vežu na axl | |
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| JP2012522513A5 (enExample) | ||
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| JP2012522512A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP2014520088A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2017522871A5 (enExample) | ||
| WO2022228563A1 (zh) | 靶向Nectin-4的抗体药物偶联物及其制备方法和用途 | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JPWO2021213434A5 (enExample) | ||
| IL308504A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |